Overview
The go-to recovery peptide.
Speeds up healing in tendons, muscles, ligaments, and gut lining.
What It Does
Community off-label use.
Stimulates angiogenesis via VEGF, activates GH receptor on tendon fibroblasts, promotes nitric-oxide signalling, suppresses NF-κB.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 2 mg | + 0.4 mL | 5 mg/mL |
| 5 mg | + 1 mL | 5 mg/mL |
| 10 mg | + 2 mL | 5 mg/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Protocol
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Weeks 1–2 | Daily | 250 mcg | Loading. Single injection near injury site; rotate. |
| Weeks 3–4 | Daily | 375 mcg | Step-up. Half-unit increment optional, many go directly to 10u / 500 mcg. |
| Weeks 5–10 | Daily | 500 mcg | Working dose. Matches Wolverine Blend BPC-157 component. |
| Aggressive (AM+PM) | Twice daily ×2 | 500 mcg | Community-aggressive: 1 mg/day split into two daily doses for acute soft-tissue injury, severe gut flare, or post-surgical recovery. Wide therapeutic window, no toxicity reported up to 2 mg/day. Taper to daily once acute phase resolves. |
| Off | 2–4 weeks | – | Standard washout. Re-cycle if continued tissue work needed. |
Where these numbers come from. This schedule is community convention, not pharmacology. BPC-157 clears fast (elimination half-life under 30 minutes in animal studies, ~15 min IV in rats) and there is no published human PK at all: the one Phase I trial (42 healthy volunteers, NCT02637284) had its results withdrawn in 2016. So “loading”, “working dose” and “washout” describe what people do, not a schedule derived from how the compound behaves in humans. Treat the table as a starting point, not a validated protocol.
8–10 wks on / 2–4 wks off (daily microdose). Aggressive twice-daily: 4–6 wks split-dose / 4 wks off.
Daily, anytime; food doesn’t affect; consistency matters.
Unisex healing peptide, no meaningful sex or cycle effect; same protocol for men and women. Limited data in both sexes; avoid in pregnancy.
Handling & Stacking
- Freeze-dried: -4°F (years stable).
- Reconstituted: 36–46°F.
- Best used within 28 days, otherwise potency gradually fades over ~4–6 weeks (structure- based estimate, no published data).
- Discard if cloudy, discoloured, or particulates.
- Pain reduction at injury site within days.
- Tissue-repair progress at 3–4 weeks.
- Gut symptoms often improve within 1–2 weeks.
- Supply math 2mg → 15 vials | 5mg → 6 vials | 10mg → 3 vials (10-wk @ 500 mcg × 7/wk)
Safety & Patient Education
- Human data = small pilots (MSK pain, interstitial cystitis, IV) + Phase II UC; none for SubQ injury dosing.
- FDA Category 2 (2023), bulk-compounding restricted.
- PCAC RECOMMENDED it for the 503A bulks list, 8–6 (Jul 2026; advisory, non-binding; FDA rulemaking pending).
- NSAIDs (ibuprofen, Advil, Aleve, aspirin): they don’t cancel out BPC-157; that’s a myth; BPC-157 works by a different route, and in animals it even protects the gut/liver from NSAID damage.
- Still skip NSAIDs during a repair cycle, because NSAIDs slow tissue healing on their own; use Tylenol (acetaminophen) for pain instead.
- Anticoagulants (warfarin, DOACs): preclinical hints at coagulation effects; monitor INR/anti-Xa if combining.
- Research compound, FDA Category 2 (2023); request a COA per lot.
- All use off-label.
- Local injection near target tissue for orthopedic use; SubQ near abdomen for systemic gut/inflammatory use.
- Cycle 4–6 wks on / 2–4 wks off.
- Stop for new lump, injection-site reaction >7 days, or GI bleeding.
- Do not use during active cancer or pregnancy/lactation, angiogenic and growth-promoting.
